Senate Insulin Bill Focuses On List Prices With Carrot For Manufacturers, Stick For PBMs
Executive Summary
US legislation attempts to address manufacturer, pharmacy benefit manager impact on patient costs in addition to health plan benefit designs. Critics suggest it’s too easy on manufacturers but that may help its chances with Republicans.
You may also be interested in...
Drug Pricing On The Right Side Of The Inflation Debate – At The Wrong Time
The US pharmaceutical industry is finally on the right side of the inflation debate, with drug price increases clearly lagging well behind overall consumer price growth. It is, however, probably too late to make a difference in the prospects of price control legislation.
Rx Pricing: Insulin Costs Would Go Up Under Senate Bill; Biden Pushes Summer Action On Broader Plan
CBO highlights the pharma-friendly nature of Senate’s plan to limit patient cost-sharing for insulin. Meanwhile, White House urges Senate to pass Democrat’s more comprehensive and pharma-negative drug pricing bill instead of waiting for the revival of the Build Back Better deal.
HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill
Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.